Virtual Library

Start Your Search

K. Hirai



Author of

  • +

    P1.05 - Poster Session with Presenters Present (ID 457)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Early Stage NSCLC
    • Presentations: 1
    • +

      P1.05-036 - A Propensity-Matched Study of Multi-Port versus Single-Port Video-Assisted Thoracoscopic Surgery for Early Lung Cancer (ID 4595)

      14:30 - 15:45  |  Author(s): K. Hirai

      • Abstract
      • Slides

      Background:
      Several thoracic surgeons have already reported the beneficial effects of single-port (SP) video-assisted thoracoscopic surgery (VATS) for the patients with lung cancer. We also analyzed surgical outcomes between SP VATS and multi-port (MP) VATS, which was defined as surgery through 3-4 ports alone, and showed the inhibitory effect of postoperative wound pain in the SP VATS (Eur J Cardiothorac Surg 2015 ). In this study, we aimed to compare the effectiveness of SP and MP video-assisted thoracoscopic surgery for stage I lung cancer.

      Methods:
      A total of 212 patients with non-small cell lung cancer underwent lobectomy via SP and MP procedure between April 2008 and June 2015 in our institute. We examined the a propensity-matched analysis, perioperative variables and short-term outcomes of both operations.

      Results:
      Propensity matching produced 80 pairs in each group. The clinical outcomes of SP /MP group were as follows. The mean Fev1.0 and maximum size of tumor was 1.88±0.32/1.65±0.41 liter and 2.8±0.3/2.7±0.3 cm, respectively. The median operation time, intraoperative blood loss was 165±35/172±26 min. and 85±25/75±26 ml. The median drainage duration and postoperative hospital stay were 1.8±0.7/1.9±0.8 and 7.5±1.9/7.2 ±1.8 days and the mean number of dissected lymph nodes was 19.8±3.8/17.5± 3.1. The number of days that was used with analgesic agents within a month after surgery was 8.1±1.2/12.5±2.5 (P<0.05). Conversion rate to open thoracotomy was 3.9/3.6 %. The overall 3-year disease free survival rate was 92/88%. As for mortality and morbidity, there was no significant difference in both groups.

      Conclusion:
      SP VATS lobectomy, showing alomost as effective as the MP VATS should be considered as a new treatment option for stage I lung cancer.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.